Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. reported a stock option grant to Chief Business & Strategy Officer Roy C. Hardiman. On January 26, 2026, he was awarded a stock option covering 190,875 shares of common stock at an exercise price of $26.31 per share.
According to the filing, 25% of the shares underlying this option vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. The option expires on January 25, 2036, and all 190,875 derivative securities are reported as directly owned.
Alumis Inc. reported that Chief Development Officer Bradley Mark Christopher received a stock option grant on January 26, 2026. The option covers 190,225 shares of common stock at an exercise price of $26.31 per share and is held directly.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continuous service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported that Chief Medical Officer Jorn Drappa received a new stock option grant. The option covers 221,450 shares of common stock at an exercise price of $26.31 per share, awarded on January 26, 2026.
According to the vesting terms, 25% of the shares vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Drappa’s continuous service under the company’s 2024 Equity Incentive Plan and subject to potential acceleration provisions.
Alumis Inc. (ALMS) reported an equity award to its Chief Financial Officer, John R. Schroer. On January 26, 2026, he was granted a stock option covering 202,225 shares of common stock at an exercise price of $26.31 per share.
These options vest over time: 25% of the underlying shares vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to Alumis under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein. On January 26, 2026, he received an option to buy 216,675 shares of common stock at an exercise price of $26.31 per share, held as a direct derivative position.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. director Srinivas Akkaraju reported an indirect purchase of Alumis common stock tied to investment entities he is associated with. On January 9, 2026, Samsara Opportunity Fund, L.P. acquired 588,235 shares of Alumis common stock at $17 per share, reported with transaction code "P." After this trade, Samsara Opportunity Fund, L.P. was shown as holding 1,853,488 shares of Alumis indirectly for the reporting person.
The filing also notes an additional 4,491,731 shares of Alumis common stock held indirectly through Samsara BioCapital, L.P. Akkaraju is a managing member or has voting and investment power in the related general partners and may be deemed to beneficially own these holdings, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Alumis Inc. received an updated ownership report from investment entities affiliated with Srinivas Akkaraju. Samsara BioCapital, L.P. reports beneficial ownership of 4,491,731 shares of Alumis common stock, representing 3.8% of the class, while Samsara Opportunity Fund, L.P. reports 1,853,488 shares, or 1.6%. Dr. Akkaraju is reported to beneficially own 6,345,219 shares in total, equal to 5.4% of Alumis' voting common stock.
The filing details a series of open-market purchases by Samsara Opportunity Fund between late November and early December 2025 at prices generally between about $7.31 and $11.005 per share, plus a purchase of 588,235 shares at $17.00 per share in Alumis' January 2026 public offering. The aggregate purchase price for these securities from November 26, 2025 through January 9, 2026 was $15,209,937.96.
Foresite Capital entities and James B. Tananbaum have updated their disclosure of ownership in Alumis Inc. common stock in this Amendment No. 3 to Schedule 13D. The filing shows that Tananbaum is deemed to beneficially own 16,189,804 shares, or 14.1% of Alumis’s common stock, through a network of Foresite funds and affiliated LLCs.
The amendment reflects dilution from Alumis issuing additional shares and new purchases, including participation in the July 2024 IPO at $16.00 per share, multiple open-market purchases in 2025, and a follow-on offering on January 8, 2026 where Fund V and Opportunity Fund V bought shares at $17.00 per share. The reporting persons state they hold the position for investment purposes and may buy more, hold, sell, or distribute shares depending on market conditions and their assessment of Alumis’s business.
Alumis Inc. reported insider activity by investment entities affiliated with Foresite Labs and related funds. On 01/08/2026, these entities executed open‑market purchases of Alumis common stock, including 117,647 shares at $17 per share and a separate purchase of 294,117 shares at $17 per share. After these trades, the reporting structures show indirect beneficial ownership positions such as 5,702,536 shares and 2,908,332 shares in specific funds, along with additional indirect holdings in other affiliated vehicles. The reporting persons, Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC, are identified as more than 10% owners, and the footnotes explain that the shares are held through various Foresite Capital and Foresite Labs entities with beneficial ownership disclaimed except for each party’s pecuniary interest.
Alumis Inc. (ALMS) received a Form 4 filing from several Foresite Capital and Foresite Labs investment entities that are 10% owners, reporting indirect ownership of Alumis common stock.
On January 8, 2026, Foresite Capital Fund V, L.P. purchased 117,647 Alumis common shares at $17 per share, bringing its indirectly reported holdings to 5,702,536 shares. On the same date, Foresite Capital Opportunity Fund V, L.P. purchased 294,117 shares at $17 per share, with indirectly reported holdings of 2,908,332 shares.
The filing also lists additional indirect common stock holdings: Foresite Capital Fund VI, L.P. with 4,247,670 shares, Labs Co-Invest V, LLC with 194,459 shares, Foresite Labs Fund I, L.P. with 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC with 1,176,470 shares. The reporting entities note that they may be deemed to have voting and dispositive power through their general partners or managing members and each disclaims group status and beneficial ownership beyond its pecuniary interest.